Pfizer Corporation

Pharmacia & Upjohn Company

Pfizer Products Inc.

Donn G Wishka

David W Piotrowski

Vincent E Groppi, Jr

Eric Jon Jacobsen

Daniel Patrick Walker

Brad A Acker

Joel Morris

Richard Charles Thomas

Gary J Cleek

Steven Charles Reitz

Stephen T Schlachter

Bruce Nelsen Rogers

Richard Allen Nugent

Jeffrey W Corbett

Jason K Myers

Michael J Murphy

Michael Luzzio

Michael R Barbachyn

Samit Kumar Bhattacharya

Fritz Reusser

Jun Xiao

Alice L Bodnar

Kendra Louise Nelson

Wade J Adams

Joel Thomas Arcari

James Alfred Southers, Jr

David R Graber

Mark R Rauckhorst

Gonghua Pan

Janice M Friis

Arthur Douglas Brosius

Irene W Althaus

The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R, R, R, A, K, M, L, L, X, Y, Y, Q, salt thereof, wherein R, R, R, A, K, L, L, W, X, Z, Z, Y, Y, Z, Z, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Pyrimidine derivatives for the treatment of abnormal cell growth

The invention provides compounds of Formula I: wherein Azabicyclo is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which &#x3b1;7 is known to be involved.

[object Object]

The invention provides compounds of Formula I: where in W is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which &#x3b1;7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo isW is a six-membered heterocyclic ring system having 1&#x2013;2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1&#x2013;2 substitutents independently selected from R. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which &#x3b1;7 is known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo isThese compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease

The invention provides compounds of Formula I:These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which &#x3b1;7 is known to be involved.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease

Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease

Substituted-heteroaryl-7-aza&lsqb;2.2.1&rsqb;bicycloheptanes for the treatment of disease

The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I ##STR1## and pyrimidine-thioalkyl and alkylethers of Formula I, where R.sub.4 is selected from the group consisting of --H or --NR.sub.15 R.sub.16 where R.sub.15 is --H and R.sub.16 is --H, C.sub.1 -C.sub.6 alkyl, --NH.sub.2 or R.sub.15 and R.sub.16 taken together with the --N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and

Thioalkyl alpha substituted pyrimidine compounds

The present invention provides novel substituted amionphenyl isoxazoline derivatives of formula I ##STR1## wherein R.sub.1 is H, alkyl, cycloalkyl, alkoxy, amino, or alkylamino; X and Y are the same and different and are H, F, or CH.sub.3 ; W is O, or S;

Substituted aminophenyl isoxazoline derivatives useful as antimicrobials

Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as

Pyrimidine-thioalkyl and alkylether compounds

Growing community of inventors

Kalamazoo, MI, United States of America

Donn G Wishka